Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

CELCBullishIndustry Newsnews

Medium materiality6/10

CELC rPFS data post-abiraterone signals potential upside

Oct 23, 2026, 5:48 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive rPFS metrics in a previously treated cohort can raise probability of CELC-related success signals and potentially a re-rating if follow-up data corroborate; however, data are interim and not a regulatory milestone, so upside is contingent on further validation and disclosures.

AI summary

What happened, with direct paths to the underlying reporting

Latest trial data show a median rPFS of 15.7 months and a six-month rPFS rate of 82.2% for patients with prior abiraterone. While not an approval, these signals could inform CELC's development strategy and potential advancement in combination regimens, subject to broader validation and longer-term outcomes.

Median rPFS: 15.7 months in prior abiraterone patients.
Six-month rPFS rate: 82.2% in the same group.
Data pertain to patients previously treated with abiraterone.
Data signals are interim; broader population data not disclosed.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

CELC rPFS data post-abiraterone signals potential upside

Celcuity Q2 loss narrows; potential near-term upside on beat

Celcuity receives FDA approval for its first product in advanced breast cancer

Celcuity reports Phase 3 superiority for gedatolisib regimens in VIKTORIA-1

Celcuity plunges after trial results, underscoring data risk in its cancer program